Investigation Launched into Medpace Holdings for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: Newsfilter
- Financial Performance Miss: Medpace's Q4 2025 financial results, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, indicating that backlog cancellations were at their highest in over a year, which undermined investor confidence.
- Stock Price Plunge: Following the disappointing financial news, Medpace's stock price plummeted by $84.30, or 15.9%, closing at $446.05 per share on February 10, 2026, directly impacting the value of investors' holdings and raising concerns about the company's stability.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Medpace Holdings regarding potential violations of federal securities laws, aiming to provide legal support for affected investors seeking to recover their losses.
- Investor Rights Advocacy: The law firm is urging all investors who suffered losses in Medpace to contact them to discuss potential claims, emphasizing the importance of protecting investor rights and seeking compensation for financial damages.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 508.520
Low
462.00
Averages
569.17
High
660.00
Current: 508.520
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Launched into Medpace Holdings for Securities Violations
- Financial Performance Miss: Medpace's Q4 2025 financial results, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, indicating that backlog cancellations were at their highest in over a year, which undermined investor confidence.
- Stock Price Plunge: Following the disappointing financial news, Medpace's stock price plummeted by $84.30, or 15.9%, closing at $446.05 per share on February 10, 2026, directly impacting the value of investors' holdings and raising concerns about the company's stability.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Medpace Holdings regarding potential violations of federal securities laws, aiming to provide legal support for affected investors seeking to recover their losses.
- Investor Rights Advocacy: The law firm is urging all investors who suffered losses in Medpace to contact them to discuss potential claims, emphasizing the importance of protecting investor rights and seeking compensation for financial damages.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor dissatisfaction with the company's management.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that the company's projected book-to-bill ratio for Q4 2025 was overstated, which misled investors about the company's financial health and could impact stock prices.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the expected 1.15, resulting in a nearly 16% drop in stock price, reflecting market disappointment and a loss of confidence in the company's performance.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent all other members in the lawsuit, demonstrating investors' proactive stance in seeking legal remedies.
See More
Class Action Lawsuit Announced for Medpace Holdings, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) for stock purchasers between April 22, 2025, and February 9, 2026, reflecting investor concerns over the company's financial transparency.
- Compensation Opportunity: Investors who purchased Medpace stock during the class period may seek compensation without any out-of-pocket fees, indicating that legal avenues provide potential economic recovery for affected investors.
- False Statement Allegations: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations, which could result in significant financial losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
Medpace Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace for investors who purchased shares between April 22, 2025, and February 9, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations of False Statements: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses when the truth emerged, highlighting serious issues with the company's governance and transparency.
- Investor Rights Protection: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, indicating the urgency of the legal process, which could affect Medpace's reputation and future financing capabilities.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating the firm's capability to handle complex securities cases, which could significantly influence the legal outcomes for Medpace.
See More
Faruqi & Faruqi Investigates Medpace Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased securities between April 22, 2025, and February 9, 2026, urging them to apply for lead plaintiff status in the federal securities class action by the June 8, 2026 deadline.
- False Statement Allegations: The complaint alleges that Medpace provided overly positive statements while concealing significant adverse facts regarding its backlog cancellation rate, leading to unrealistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Stock Price Volatility: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the guidance of 1.15, Medpace's stock price plummeted from $530.35 to $446.05, a decline of over 15.9%, indicating market concerns about the company's financial health.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Medpace's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for affected investors.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Medpace Holdings, Inc. is facing a class action lawsuit due to misleading positive statements made between April 22, 2025, and February 9, 2026, under case number 1:26-cv-00346, highlighting serious deficiencies in the company's financial transparency.
- Stock Price Plummets: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price dropped from $530.35 to $446.05, a decline exceeding 15.9%, reflecting market disappointment in the company's outlook.
- Investor Loss Compensation: Levi & Korsinsky is committed to ensuring full compensation for investors who suffered losses due to corporate misrepresentations, urging shareholders to step forward before the June 8, 2026 deadline to seek justice as lead plaintiffs.
- Legal Team Expertise: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has a team of over 70 employees, consistently ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing their extensive experience in complex securities litigation.
See More
Investigation Launched into Medpace Holdings for Securities Violations
- Financial Performance Miss: Medpace's Q4 2025 financial results, released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, indicating that backlog cancellations were at their highest in over a year, which undermined investor confidence.
- Stock Price Plunge: Following the disappointing financial news, Medpace's stock price plummeted by $84.30, or 15.9%, closing at $446.05 per share on February 10, 2026, directly impacting the value of investors' holdings and raising concerns about the company's stability.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into Medpace Holdings regarding potential violations of federal securities laws, aiming to provide legal support for affected investors seeking to recover their losses.
- Investor Rights Advocacy: The law firm is urging all investors who suffered losses in Medpace to contact them to discuss potential claims, emphasizing the importance of protecting investor rights and seeking compensation for financial damages.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor dissatisfaction with the company's management.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that the company's projected book-to-bill ratio for Q4 2025 was overstated, which misled investors about the company's financial health and could impact stock prices.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the expected 1.15, resulting in a nearly 16% drop in stock price, reflecting market disappointment and a loss of confidence in the company's performance.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent all other members in the lawsuit, demonstrating investors' proactive stance in seeking legal remedies.
See More
Class Action Lawsuit Announced for Medpace Holdings, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) for stock purchasers between April 22, 2025, and February 9, 2026, reflecting investor concerns over the company's financial transparency.
- Compensation Opportunity: Investors who purchased Medpace stock during the class period may seek compensation without any out-of-pocket fees, indicating that legal avenues provide potential economic recovery for affected investors.
- False Statement Allegations: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations, which could result in significant financial losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
See More
Medpace Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace for investors who purchased shares between April 22, 2025, and February 9, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations of False Statements: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses when the truth emerged, highlighting serious issues with the company's governance and transparency.
- Investor Rights Protection: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, indicating the urgency of the legal process, which could affect Medpace's reputation and future financing capabilities.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating the firm's capability to handle complex securities cases, which could significantly influence the legal outcomes for Medpace.
See More
Faruqi & Faruqi Investigates Medpace Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased securities between April 22, 2025, and February 9, 2026, urging them to apply for lead plaintiff status in the federal securities class action by the June 8, 2026 deadline.
- False Statement Allegations: The complaint alleges that Medpace provided overly positive statements while concealing significant adverse facts regarding its backlog cancellation rate, leading to unrealistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Stock Price Volatility: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the guidance of 1.15, Medpace's stock price plummeted from $530.35 to $446.05, a decline of over 15.9%, indicating market concerns about the company's financial health.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Medpace's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for affected investors.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Medpace Holdings, Inc. is facing a class action lawsuit due to misleading positive statements made between April 22, 2025, and February 9, 2026, under case number 1:26-cv-00346, highlighting serious deficiencies in the company's financial transparency.
- Stock Price Plummets: Following the announcement of a fourth-quarter book-to-bill ratio of 1.04 on February 9, 2026, significantly below the expected 1.15, Medpace's stock price dropped from $530.35 to $446.05, a decline exceeding 15.9%, reflecting market disappointment in the company's outlook.
- Investor Loss Compensation: Levi & Korsinsky is committed to ensuring full compensation for investors who suffered losses due to corporate misrepresentations, urging shareholders to step forward before the June 8, 2026 deadline to seek justice as lead plaintiffs.
- Legal Team Expertise: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has a team of over 70 employees, consistently ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing their extensive experience in complex securities litigation.
See More
